Impact of methylenetetrahydrofolate reductase (MTHFR) A1298C gene polymorphism on the outcome of methotrexate treatment in a sample of Egyptian rheumatoid arthritis patients
Conclusion: Our study proved that MTHFR A1298C SNP can predict clinical outcome of MTX treatment as regards treatment efficacy and toxicity in Egyptian rheumatoid arthritis patients.
Source: Alexandria Journal of Medicine - Category: General Medicine Source Type: research
More News: Arthritis | Egypt Health | General Medicine | Genetics | Methotrexate | Rheumatoid Arthritis | Rheumatology | Study | Toxicology